ProCE Banner Activity

ExpressPoints: Personalizing Therapy With Factor VIII Prophylaxis in Hemophilia A

Slideset Download
Download this summary slideset with essential expert insights on the clinical management of patients with hemophilia A.

Released: November 05, 2020

Expiration: November 04, 2021

No longer available for credit.

Share

Faculty

Michael Callaghan

Michael Callaghan, MD

Associate Professor
Department of Hematology
Wayne State University
Hematologist
Division of Hematology/Oncology
Childrens Hospital of Michigan
Detroit, Michigan

Miguel A. Escobar

Miguel A. Escobar, MD

Professor of Medicine and Pediatrics
Division of Hematology
McGovern Medical School
Director
Gulf States Hemophilia and Thrombophilia Center
Houston, Texas

Guy Young

Guy Young, MD

Director, Hemostasis and Thrombosis Center
Director, Clinical Coagulation Laboratory
Cancer and Blood Disorders Institute
Children's Hospital Los Angeles
Professor of Pediatrics
Division of Hematology/Oncology
Department of Pediatrics
University of Southern California Keck School of Medicine
Los Angeles, California

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Takeda Pharm USA

Faculty Disclosure

Primary Author

Michael Callaghan, MD

Associate Professor
Department of Hematology
Wayne State University
Hematologist
Division of Hematology/Oncology
Childrens Hospital of Michigan
Detroit, Michigan

Michael U. Callaghan, MD, has disclosed that he has received honoraria for participating on advisory boards for Bayer, Biomarin, Bioverativ, Blue Bird Bio, Global Blood Therapeutics, Grifols, Hema Biologics, Octapharma, Pfizer, Roche, Shire, and Spark. He also has participated on Speakers Bureaus for Bayer, Biomarin, Global Blood Therapeutics, NovoNordisk, Roche/Genentech, and Shire; has received research support from Pfizer and Shire; and has been an investigator on clinical trials conducted by Amgen, Biomarin, Global Blood Therapeutics, NovoNordisk, Pfizer, Roche/Genentech, and Sancillio. He also owns stock in Alnylum.

Miguel A. Escobar, MD

Professor of Medicine and Pediatrics
Division of Hematology
McGovern Medical School
Director
Gulf States Hemophilia and Thrombophilia Center
Houston, Texas

Miguel A. Escobar, MD, has disclosed that he has received consulting fees from CSL Behring, Genentech/Roche, NovoNordisk, Sanofi, and Takeda.

Guy Young, MD

Director, Hemostasis and Thrombosis Center
Director, Clinical Coagulation Laboratory
Cancer and Blood Disorders Institute
Children's Hospital Los Angeles
Professor of Pediatrics
Division of Hematology/Oncology
Department of Pediatrics
University of Southern California Keck School of Medicine
Los Angeles, California

Guy A. Young, MD, has disclosed that he has received funds for research support from Genentech/Roche, Grifols, and Takeda; and consulting fees from BioMarin, Genentech/Roche, Grifols, Novo Nordisk, Sanofi, Spark, Takeda, and UniQure.